PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33704910-0	2021	Trimetazidine improved adriamycin-induced cardiomyopathy by downregulating TNF-alpha, BAX, and VEGF immunoexpression via an antioxidant mechanism.	Trimetazidine	0-13	vascular endothelial growth factor A	Rattus norvegicus	95-99	
30057668-4	2018	After 24 h, post I/R treatment with trimetazidine significantly reduced serum blood urea nitrogen and creatinine levels and tubular injury accompanied with upregulation of hypoxia-inducible factor- (HIF-) 1alpha, vascular endothelial growth factor (VEGF), and Bcl-2 expression.	Trimetazidine	36-49	vascular endothelial growth factor A	Rattus norvegicus	213-247	
30057668-4	2018	After 24 h, post I/R treatment with trimetazidine significantly reduced serum blood urea nitrogen and creatinine levels and tubular injury accompanied with upregulation of hypoxia-inducible factor- (HIF-) 1alpha, vascular endothelial growth factor (VEGF), and Bcl-2 expression.	Trimetazidine	36-49	vascular endothelial growth factor A	Rattus norvegicus	249-253	
30057668-5	2018	After 5 d, post I/R treatment with trimetazidine reduced renal tubular cell necrosis and apoptosis with upregulation of HIF-1alpha-VEGF and tissue inhibitors of metalloproteinase activities, attenuation of matrix metalloproteinase activities, and alteration of the ratio of Bax to Bcl-2 levels.	Trimetazidine	35-48	vascular endothelial growth factor A	Rattus norvegicus	131-135	
12768069-12	2003	In the TMZ group, MDA and VEGF levels and neoangiogenesis were significantly less than those of the hypertonic dextrose group.	Trimetazidine	7-10	vascular endothelial growth factor A	Rattus norvegicus	26-30